Ensign Peak Advisors, Inc - CTI BIOPHARMA CORP ownership

Quarter-by-quarter ownership
Ensign Peak Advisors, Inc ownership history of CTI BIOPHARMA CORP
ValueSharesWeighting
Q1 2023$5,569,460
-30.1%
1,326,0620.0%0.01%
-33.3%
Q4 2022$7,969,633
+93.9%
1,326,062
+87.8%
0.02%
+80.0%
Q3 2022$4,111,000
+361.9%
706,277
+373.7%
0.01%
+400.0%
Q2 2022$890,000149,0910.00%
Other shareholders
CTI BIOPHARMA CORP shareholders Q3 2023
NameSharesValueWeighting ↓
Stonepine Capital Management, LLC 8,800,358$21,825,00010.02%
CAXTON CORP 2,239,300$5,553,0004.54%
Altium Capital Management LP 2,185,000$5,419,0001.49%
SILVERARC CAPITAL MANAGEMENT, LLC 1,483,829$3,680,0001.49%
Ghost Tree Capital, LLC 1,200,000$2,976,0001.07%
Lion Point Capital, LP 1,223,595$3,034,0000.81%
BVF INC/IL 8,929,690$22,146,0000.80%
NEA Management Company, LLC 7,140,450$17,708,0000.36%
Knott David M Jr 221,079$548,0000.19%
Lakeside Advisors, INC. 97,780$242,0000.18%
View complete list of CTI BIOPHARMA CORP shareholders